BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18469201)

  • 1. Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism.
    Satapati S; He T; Inagaki T; Potthoff M; Merritt ME; Esser V; Mangelsdorf DJ; Kliewer SA; Browning JD; Burgess SC
    Diabetes; 2008 Aug; 57(8):2012-21. PubMed ID: 18469201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazoxide attenuates insulin secretion and hepatic lipogenesis in zucker diabetic fatty rats.
    Alemzadeh R; Tushaus K
    Med Sci Monit; 2005 Dec; 11(12):BR439-48. PubMed ID: 16319780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.
    Chou CJ; Haluzik M; Gregory C; Dietz KR; Vinson C; Gavrilova O; Reitman ML
    J Biol Chem; 2002 Jul; 277(27):24484-9. PubMed ID: 11994294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensatory increases in nuclear PGC1alpha protein are primarily associated with subsarcolemmal mitochondrial adaptations in ZDF rats.
    Holloway GP; Gurd BJ; Snook LA; Lally J; Bonen A
    Diabetes; 2010 Apr; 59(4):819-28. PubMed ID: 20103701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.
    Nemanich S; Rani S; Shoghi K
    Obesity (Silver Spring); 2013 Dec; 21(12):2522-9. PubMed ID: 23512563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
    Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
    Coletta DK; Fernandez M; Cersosimo E; Gastaldelli A; Musi N; DeFronzo RA
    Diabet Med; 2015 May; 32(5):657-64. PubMed ID: 25484175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
    Kim H; Haluzik M; Asghar Z; Yau D; Joseph JW; Fernandez AM; Reitman ML; Yakar S; Stannard B; Heron-Milhavet L; Wheeler MB; LeRoith D
    Diabetes; 2003 Jul; 52(7):1770-8. PubMed ID: 12829645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ileal interposition surgery targets the hepatic TGF-β pathway, influencing gluconeogenesis and mitochondrial bioenergetics in the UCD-T2DM rat model of diabetes.
    Hung C; Napoli E; Ross-Inta C; Graham J; Flores-Torres AL; Stanhope KL; Froment P; Havel PJ; Giulivi C
    FASEB J; 2019 Oct; 33(10):11270-11283. PubMed ID: 31307210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats.
    Bonen A; Holloway GP; Tandon NN; Han XX; McFarlan J; Glatz JF; Luiken JJ
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1202-12. PubMed ID: 19675275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
    Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.
    Patterson RE; Kalavalapalli S; Williams CM; Nautiyal M; Mathew JT; Martinez J; Reinhard MK; McDougall DJ; Rocca JR; Yost RA; Cusi K; Garrett TJ; Sunny NE
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E484-94. PubMed ID: 26814015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
    Metais C; Forcheron F; Abdallah P; Basset A; Del Carmine P; Bricca G; Beylot M
    Metabolism; 2008 Jul; 57(7):946-53. PubMed ID: 18555836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electroacupuncture improves glucose and lipid metabolism by regulating APN/AMPK/PPARα signaling of skeletal muscle in Zucker diabetic obese rats].
    Duan HR; Li R; Song SS; Hu SQ; Zhuang ST; Li QY
    Zhen Ci Yan Jiu; 2021 Nov; 46(11):907-13. PubMed ID: 34865326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity.
    Rauckhorst AJ; Gray LR; Sheldon RD; Fu X; Pewa AD; Feddersen CR; Dupuy AJ; Gibson-Corley KN; Cox JE; Burgess SC; Taylor EB
    Mol Metab; 2017 Nov; 6(11):1468-1479. PubMed ID: 29107293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.